Predictive power of sexual hormones and tumor markers in endometrial cancer

Archives of Gynecology and Obstetrics

Volumn 281, Issue 4, 2010, Pages 709-715

  Kanat Pektas, Mine ^a,b   Yenicesu, Okan ^a   Gungor, Tayfun ^a   Bilge, Umit ^a  

^a ZEKAI TAHIR BURAK WOMEN S HEALTH EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Ertugrul Gazi Mah Kutlugun Sok   (Turkey)

Author keywords

CA 125; Endometrial cancer; Prediction; Prognosis; Prolactin

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PROLACTIN; SEX HORMONE; THYROTROPIN; TUMOR MARKER;

ADULT; ARTICLE; BODY MASS; CANCER GRADING; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIUM CANCER; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THYROTROPIN BLOOD LEVEL;

CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; GONADAL STEROID HORMONES; HUMANS; MIDDLE AGED; PITUITARY HORMONES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 77950628262     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-009-1228-4     Document Type: Article

References (23)

1. Sonoda Y, Barakat RR (2006) Screening and prevention of gynecologic cancer: endometrial cancer. Best Pract Res Clin Obstet Gynaecol 20:363-377
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249
3. Chu W, Fyles A, Sellers E, McCready D, Murphy J, Pal T (2007) Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis 28(10):2139-2142
4. Schimp VL, Ali-Fehmi R, Solomon LA, Hammoud A, Pansare V, Morris RT (2006) The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level? Gynecol Oncol 102:440-446
5. DiCristafano A, Ellenson LH (2007) Endometrial carcinoma. Annu Rev Pathol 2:57-85
6. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzini AR (2004) Serum tumor markers in management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 58:24-38
7. Hsieh CH, ChangChien CC, Lin H, Huang EY, Huang CC, Lan KC (2002) Can a pre-operative CA-125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol 86:28-33
8. Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH (2005) Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 50:585-590
9. Patsner B, Mann WJ, Cohen H, Loesch M (1988) Predictive value of preoperative serum CA-125 levels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol 158:399-402
10. Aalders JG, Abeler V, Kolstad P (1984) Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 17:85-103 (Pubitemid 14176295)
11. International Federation of Gynecology and Obstetrics (FIGO) (1989) Annual report on the results of treatment in gynecologic cancer. Int J Gynecol Obstet 28:189-193
12. International Federation of Gynecology and Obstetrics (FIGO) (1971) Classification and staging of malignant tumors in female pelvis. Int J Gynecol Obstet 9:172-180
13. Bochkareva NV, Kolomiets LA, Kondakova IV, Stukanov SL, Tropina TV, Muntian AB (2008) Sex hormones in the systemic and local circulation in endometrial hyperplasia and neoplasia: correlation with the activity of estrogen-metabolizing enzymes. Vopr Onkol 54(6):729-733
14. Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E, Maxwell GL, Lu K, Lokshin A (2007) Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol 107(1):58-65
15. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P (2001) Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 943:296-315
16. Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP (2006) Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand 85(12):1501-1505
17. Santala M, Talvensaari-Mattila A, Kauppila A (2003) Peritoneal cytology and preoperative serum CA 125 level are important prognostic indicators of overall survival in advanced endometrial cancer. Anticancer Res 23(3C):3097-3103
18. Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE (2009) Biological significance of prolactin in gynecologic cancers. Cancer Res 69(12):5226-5233
19. Clapp C, Lopez-Gomez FJ, Nava G, Corbacho A, Torner L, Macotela Y et al (1998) Expression of prolactin mRNA and of prolactin-like proteins in endothelial cells: evidence for autocrine effects. J Endocrinol 158:137-144
20. Am Corbacho, De La Ecalera GM, Clapp C (2002) Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 173:219-238
21. Portier CJ (2002) Endocrine dismodulation and cancer. Neuro Endocrinol Lett 23(suppl 2):43-47
22. Yildirim M, Bozkurt N, Kurdoglu M, Taskiran C, Oktem M, Dilek KU (2007) Histopathologic findings in women with postmenopausal bleeding: implication for endometrial thickness and circulating levels of sex steroid hormones. Arch Gynecol Obstet 276(4):305-310
23. Frumovitz M, Singh DK, Meyer L, Smith DH, Wertheim I, Resnik E, Bodurka DC (2004) Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 95(3):463-468